• Users Online: 240
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2020  |  Volume : 9  |  Issue : 4  |  Page : 125

Editor's Page October 2020

Editor-in-Chief, Journal of Clinical and Preventive Cardiology, Gurugram, Haryana, India

Date of Web Publication09-Feb-2021

Correspondence Address:
Dr. Ravi R Kasliwal
Adjunct Professor Cardiology (NBE) Chairman, Clinical and Preventive Cardiology, Medanta-The Medicity, Sector 38, Gurugram - 122 001, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2250-3528.308971

Rights and Permissions

How to cite this article:
Kasliwal RR. Editor's Page October 2020. J Clin Prev Cardiol 2020;9:125

How to cite this URL:
Kasliwal RR. Editor's Page October 2020. J Clin Prev Cardiol [serial online] 2020 [cited 2022 Jan 26];9:125. Available from: https://www.jcpconline.org/text.asp?2020/9/4/125/308971

When you pick up this issue of JCPC, vaccination for the currently ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic would have already been widely used all over the globe and India. And yet, everybody would know the danger is far from over. However, there would be hope for a better 2021! Furthermore, physical distancing, masking, and frequent sanitizing would continue for possibly a much longer time.

The first original article, from the Philippines, “Incidence and Severity of Tricuspid Regurgitation after Permanent Pacemaker: Single-Center Cohort in the Philippines” talks about a common problem, tricuspid regurgitation, after permanent pacemaker implantation. One-fourth of their patients developed moderate tricuspid regurgitation, underscoring the magnitude of this problem.

The second article from the Nizam's Institute of Medical Sciences “Evaluation of Diagnostic Utility of Pentraxim-3 in Acute Coronary Syndrome Patients: A Pilot Study from Tertiary Care Hospital in South India” demonstrates the use of pentraxim-3 levels in acute coronary syndrome. Certainly, a new thought. All of us in clinical cardiology are obsessed with the use of troponins, and this small study may be the harbinger of a new concept.

The third article by Satyendra Tewari et al. from Lucknow, Bhubaneshwar, and Mysore on “Evaluation of Left Ventricular Function in Patients with Systemic Lupus Erythematosus (SLE): Association of Tissue Doppler and Strain Imaging with Disease Activity” is an interesting thought on subclinical left ventricular dysfunction in patients with SLE using strain imaging, a new but robust echocardiographic technique. It seems that even young patients of SLE have not only got impaired left ventricular systolic function but also diastolic dysfunction. These findings do not augur well for these patients. Long-term studies are required. It seems to me that “Cardio-Rheumatology” is already here.

The fourth article from Wani group titled “Incidence, Risk Factors, and Outcomes of Contrast-Associated Nephropathy following Percutaneous Coronary Intervention” is a single-center study on contrast-associated acute kidney injury (AKI) following percutaneous coronary interventions. The study encompasses 500 patients and found that the incidence of AKI was 10%, and the risk factors were diabetes mellitus, heart failure, left ventricular dysfunction, low creatinine clearance, and high volume of contrast medium. Here is clearly an area where cardiologists and nephrologists need to work closely together for the patient and keep discussing with the attendants as well. Two experts in this field – Dr. Vijay Kher and Dr. Dinesh Bansal – have contributed a thought-provoking, “must read” editorial comment on this article with valuable inputs. In the cardiac catheterization laboratory, it is important to note not only the amount of radiation exposed to the patient but also the quantum of contrast material.

A pilot study from Malaysia “Apixaban versus Warfarin in Patients with Left Ventricular Thrombus: A Pilot Prospective Randomized Outcome Blinded Study Investigating Size Reduction or Resolution of Left Ventricular Thrombus” has given a new thought for the primary treatment of left ventricular thrombus resolution. This pilot study is so meticulously done that, at the end, I thought it could have been a bigger study with far-reaching implications.

The last study from Rajesh Nepal's group “Acute Decompensated Heart failure with Reduced Ejection Fraction: Common Etiological Cause and Predictor of Mortality in the Nepalese Population” gives an insight into the reasons for early mortality in patients with acute decompensated heart failure in Nepal. In the authors' own words, “the strength of the present study is that it presents the real-world data of the region."

Different people will remember year 2020 differently – there was no joy; only gloom, worry, despair, and death! And yet, I marvel at the human spirit and the human resilience. People had a helping for those in need. Generosity was seen and felt. We survived, and there was so much to learn and imbibe.

My salute to those doctors, nurses, paramedics, police force, and others who gave their lives in the pandemic when they could have just walked away!


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded122    
    Comments [Add]    

Recommend this journal